Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial

Background Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial analysis from JAVELIN Merkel 200, a phase 2, prospective, open-label, single-arm trial in mMCC, avelumab—a human anti–prog...

Full description

Saved in:
Bibliographic Details
Published inJournal for immunotherapy of cancer Vol. 6; no. 1; p. 7
Main Authors Kaufman, Howard L., Russell, Jeffery S., Hamid, Omid, Bhatia, Shailender, Terheyden, Patrick, D’Angelo, Sandra P., Shih, Kent C., Lebbé, Céleste, Milella, Michele, Brownell, Isaac, Lewis, Karl D., Lorch, Jochen H., von Heydebreck, Anja, Hennessy, Meliessa, Nghiem, Paul
Format Journal Article
LanguageEnglish
Published London BioMed Central 19.01.2018
BioMed Central Ltd
BMJ Publishing Group LTD
BMJ Publishing Group
Subjects
Online AccessGet full text
ISSN2051-1426
2051-1426
DOI10.1186/s40425-017-0310-x

Cover

Abstract Background Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial analysis from JAVELIN Merkel 200, a phase 2, prospective, open-label, single-arm trial in mMCC, avelumab—a human anti–programmed death-ligand 1 (PD-L1) monoclonal antibody—showed promising efficacy and a safety profile that was generally manageable and tolerable. Here, we report the efficacy of avelumab after ≥1 year of follow-up in patients with distant mMCC that had progressed following prior chemotherapy for metastatic disease. Patients and methods Patients received avelumab 10 mg/kg by 1-h intravenous infusion every 2 weeks until confirmed disease progression, unacceptable toxicity, or withdrawal. The primary endpoint was best overall response. Secondary endpoints included duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Results Patients ( N  = 88) were followed for a minimum of 12 months. The confirmed objective response rate was 33.0% (95% CI, 23.3%-43.8%; complete response: 11.4%). An estimated 74% of responses lasted ≥1 year, and 72.4% of responses were ongoing at data cutoff. Responses were durable, with the median DOR not yet reached (95% CI, 18.0 months-not estimable), and PFS was prolonged; 1-year PFS and OS rates were 30% (95% CI, 21%-41%) and 52% (95% CI, 41%-62%), respectively. Median OS was 12.9 months (95% CI, 7.5-not estimable). Subgroup analyses suggested a higher probability of response in patients receiving fewer prior lines of systemic therapy, with a lower baseline disease burden, and with PD-L1–positive tumors; however, durable responses occurred irrespective of baseline factors, including tumor Merkel cell polyomavirus status. Conclusions With longer follow-up, avelumab continues to show durable responses and promising survival outcomes in patients with distant mMCC whose disease had progressed after chemotherapy. Trial registration Clinicaltrials.gov identifier: NCT02155647.
AbstractList Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial analysis from JAVELIN Merkel 200, a phase 2, prospective, open-label, single-arm trial in mMCC, avelumab-a human anti-programmed death-ligand 1 (PD-L1) monoclonal antibody-showed promising efficacy and a safety profile that was generally manageable and tolerable. Here, we report the efficacy of avelumab after ≥1 year of follow-up in patients with distant mMCC that had progressed following prior chemotherapy for metastatic disease. Patients received avelumab 10 mg/kg by 1-h intravenous infusion every 2 weeks until confirmed disease progression, unacceptable toxicity, or withdrawal. The primary endpoint was best overall response. Secondary endpoints included duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Patients (N = 88) were followed for a minimum of 12 months. The confirmed objective response rate was 33.0% (95% CI, 23.3%-43.8%; complete response: 11.4%). An estimated 74% of responses lasted ≥1 year, and 72.4% of responses were ongoing at data cutoff. Responses were durable, with the median DOR not yet reached (95% CI, 18.0 months-not estimable), and PFS was prolonged; 1-year PFS and OS rates were 30% (95% CI, 21%-41%) and 52% (95% CI, 41%-62%), respectively. Median OS was 12.9 months (95% CI, 7.5-not estimable). Subgroup analyses suggested a higher probability of response in patients receiving fewer prior lines of systemic therapy, with a lower baseline disease burden, and with PD-L1-positive tumors; however, durable responses occurred irrespective of baseline factors, including tumor Merkel cell polyomavirus status. With longer follow-up, avelumab continues to show durable responses and promising survival outcomes in patients with distant mMCC whose disease had progressed after chemotherapy. Clinicaltrials.gov identifier: NCT02155647.
BackgroundMerkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial analysis from JAVELIN Merkel 200, a phase 2, prospective, open-label, single-arm trial in mMCC, avelumab—a human anti–programmed death-ligand 1 (PD-L1) monoclonal antibody—showed promising efficacy and a safety profile that was generally manageable and tolerable. Here, we report the efficacy of avelumab after ≥1 year of follow-up in patients with distant mMCC that had progressed following prior chemotherapy for metastatic disease.Patients and methodsPatients received avelumab 10 mg/kg by 1-h intravenous infusion every 2 weeks until confirmed disease progression, unacceptable toxicity, or withdrawal. The primary endpoint was best overall response. Secondary endpoints included duration of response (DOR), progression-free survival (PFS), and overall survival (OS).ResultsPatients (N = 88) were followed for a minimum of 12 months. The confirmed objective response rate was 33.0% (95% CI, 23.3%-43.8%; complete response: 11.4%). An estimated 74% of responses lasted ≥1 year, and 72.4% of responses were ongoing at data cutoff. Responses were durable, with the median DOR not yet reached (95% CI, 18.0 months-not estimable), and PFS was prolonged; 1-year PFS and OS rates were 30% (95% CI, 21%-41%) and 52% (95% CI, 41%-62%), respectively. Median OS was 12.9 months (95% CI, 7.5-not estimable). Subgroup analyses suggested a higher probability of response in patients receiving fewer prior lines of systemic therapy, with a lower baseline disease burden, and with PD-L1–positive tumors; however, durable responses occurred irrespective of baseline factors, including tumor Merkel cell polyomavirus status.ConclusionsWith longer follow-up, avelumab continues to show durable responses and promising survival outcomes in patients with distant mMCC whose disease had progressed after chemotherapy.Trial registrationClinicaltrials.gov identifier: NCT02155647.
Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial analysis from JAVELIN Merkel 200, a phase 2, prospective, open-label, single-arm trial in mMCC, avelumab-a human anti-programmed death-ligand 1 (PD-L1) monoclonal antibody-showed promising efficacy and a safety profile that was generally manageable and tolerable. Here, we report the efficacy of avelumab after ≥1 year of follow-up in patients with distant mMCC that had progressed following prior chemotherapy for metastatic disease.BACKGROUNDMerkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial analysis from JAVELIN Merkel 200, a phase 2, prospective, open-label, single-arm trial in mMCC, avelumab-a human anti-programmed death-ligand 1 (PD-L1) monoclonal antibody-showed promising efficacy and a safety profile that was generally manageable and tolerable. Here, we report the efficacy of avelumab after ≥1 year of follow-up in patients with distant mMCC that had progressed following prior chemotherapy for metastatic disease.Patients received avelumab 10 mg/kg by 1-h intravenous infusion every 2 weeks until confirmed disease progression, unacceptable toxicity, or withdrawal. The primary endpoint was best overall response. Secondary endpoints included duration of response (DOR), progression-free survival (PFS), and overall survival (OS).PATIENTS AND METHODSPatients received avelumab 10 mg/kg by 1-h intravenous infusion every 2 weeks until confirmed disease progression, unacceptable toxicity, or withdrawal. The primary endpoint was best overall response. Secondary endpoints included duration of response (DOR), progression-free survival (PFS), and overall survival (OS).Patients (N = 88) were followed for a minimum of 12 months. The confirmed objective response rate was 33.0% (95% CI, 23.3%-43.8%; complete response: 11.4%). An estimated 74% of responses lasted ≥1 year, and 72.4% of responses were ongoing at data cutoff. Responses were durable, with the median DOR not yet reached (95% CI, 18.0 months-not estimable), and PFS was prolonged; 1-year PFS and OS rates were 30% (95% CI, 21%-41%) and 52% (95% CI, 41%-62%), respectively. Median OS was 12.9 months (95% CI, 7.5-not estimable). Subgroup analyses suggested a higher probability of response in patients receiving fewer prior lines of systemic therapy, with a lower baseline disease burden, and with PD-L1-positive tumors; however, durable responses occurred irrespective of baseline factors, including tumor Merkel cell polyomavirus status.RESULTSPatients (N = 88) were followed for a minimum of 12 months. The confirmed objective response rate was 33.0% (95% CI, 23.3%-43.8%; complete response: 11.4%). An estimated 74% of responses lasted ≥1 year, and 72.4% of responses were ongoing at data cutoff. Responses were durable, with the median DOR not yet reached (95% CI, 18.0 months-not estimable), and PFS was prolonged; 1-year PFS and OS rates were 30% (95% CI, 21%-41%) and 52% (95% CI, 41%-62%), respectively. Median OS was 12.9 months (95% CI, 7.5-not estimable). Subgroup analyses suggested a higher probability of response in patients receiving fewer prior lines of systemic therapy, with a lower baseline disease burden, and with PD-L1-positive tumors; however, durable responses occurred irrespective of baseline factors, including tumor Merkel cell polyomavirus status.With longer follow-up, avelumab continues to show durable responses and promising survival outcomes in patients with distant mMCC whose disease had progressed after chemotherapy.CONCLUSIONSWith longer follow-up, avelumab continues to show durable responses and promising survival outcomes in patients with distant mMCC whose disease had progressed after chemotherapy.Clinicaltrials.gov identifier: NCT02155647.TRIAL REGISTRATIONClinicaltrials.gov identifier: NCT02155647.
Background Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial analysis from JAVELIN Merkel 200, a phase 2, prospective, open-label, single-arm trial in mMCC, avelumab—a human anti–programmed death-ligand 1 (PD-L1) monoclonal antibody—showed promising efficacy and a safety profile that was generally manageable and tolerable. Here, we report the efficacy of avelumab after ≥1 year of follow-up in patients with distant mMCC that had progressed following prior chemotherapy for metastatic disease. Patients and methods Patients received avelumab 10 mg/kg by 1-h intravenous infusion every 2 weeks until confirmed disease progression, unacceptable toxicity, or withdrawal. The primary endpoint was best overall response. Secondary endpoints included duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Results Patients ( N  = 88) were followed for a minimum of 12 months. The confirmed objective response rate was 33.0% (95% CI, 23.3%-43.8%; complete response: 11.4%). An estimated 74% of responses lasted ≥1 year, and 72.4% of responses were ongoing at data cutoff. Responses were durable, with the median DOR not yet reached (95% CI, 18.0 months-not estimable), and PFS was prolonged; 1-year PFS and OS rates were 30% (95% CI, 21%-41%) and 52% (95% CI, 41%-62%), respectively. Median OS was 12.9 months (95% CI, 7.5-not estimable). Subgroup analyses suggested a higher probability of response in patients receiving fewer prior lines of systemic therapy, with a lower baseline disease burden, and with PD-L1–positive tumors; however, durable responses occurred irrespective of baseline factors, including tumor Merkel cell polyomavirus status. Conclusions With longer follow-up, avelumab continues to show durable responses and promising survival outcomes in patients with distant mMCC whose disease had progressed after chemotherapy. Trial registration Clinicaltrials.gov identifier: NCT02155647.
Abstract Background Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial analysis from JAVELIN Merkel 200, a phase 2, prospective, open-label, single-arm trial in mMCC, avelumab—a human anti–programmed death-ligand 1 (PD-L1) monoclonal antibody—showed promising efficacy and a safety profile that was generally manageable and tolerable. Here, we report the efficacy of avelumab after ≥1 year of follow-up in patients with distant mMCC that had progressed following prior chemotherapy for metastatic disease. Patients and methods Patients received avelumab 10 mg/kg by 1-h intravenous infusion every 2 weeks until confirmed disease progression, unacceptable toxicity, or withdrawal. The primary endpoint was best overall response. Secondary endpoints included duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Results Patients (N = 88) were followed for a minimum of 12 months. The confirmed objective response rate was 33.0% (95% CI, 23.3%-43.8%; complete response: 11.4%). An estimated 74% of responses lasted ≥1 year, and 72.4% of responses were ongoing at data cutoff. Responses were durable, with the median DOR not yet reached (95% CI, 18.0 months-not estimable), and PFS was prolonged; 1-year PFS and OS rates were 30% (95% CI, 21%-41%) and 52% (95% CI, 41%-62%), respectively. Median OS was 12.9 months (95% CI, 7.5-not estimable). Subgroup analyses suggested a higher probability of response in patients receiving fewer prior lines of systemic therapy, with a lower baseline disease burden, and with PD-L1–positive tumors; however, durable responses occurred irrespective of baseline factors, including tumor Merkel cell polyomavirus status. Conclusions With longer follow-up, avelumab continues to show durable responses and promising survival outcomes in patients with distant mMCC whose disease had progressed after chemotherapy. Trial registration Clinicaltrials.gov identifier: NCT02155647.
ArticleNumber 7
Audience Academic
Author Kaufman, Howard L.
Russell, Jeffery S.
Shih, Kent C.
Milella, Michele
Bhatia, Shailender
Brownell, Isaac
Terheyden, Patrick
Hamid, Omid
Lebbé, Céleste
Hennessy, Meliessa
von Heydebreck, Anja
D’Angelo, Sandra P.
Nghiem, Paul
Lewis, Karl D.
Lorch, Jochen H.
Author_xml – sequence: 1
  givenname: Howard L.
  surname: Kaufman
  fullname: Kaufman, Howard L.
  email: hk553@cinj.rutgers.edu
  organization: Rutgers Cancer Institute of New Jersey, Present Address: Replimune Inc
– sequence: 2
  givenname: Jeffery S.
  surname: Russell
  fullname: Russell, Jeffery S.
  organization: H. Lee Moffitt Cancer Center, Present Address: Immunocore, Ltd
– sequence: 3
  givenname: Omid
  surname: Hamid
  fullname: Hamid, Omid
  organization: The Angeles Clinic and Research Institute
– sequence: 4
  givenname: Shailender
  surname: Bhatia
  fullname: Bhatia, Shailender
  organization: University of Washington Medical Center
– sequence: 5
  givenname: Patrick
  surname: Terheyden
  fullname: Terheyden, Patrick
  organization: University of Lübeck
– sequence: 6
  givenname: Sandra P.
  surname: D’Angelo
  fullname: D’Angelo, Sandra P.
  organization: Memorial Sloan Kettering Cancer Center & Weill Cornell Medical College
– sequence: 7
  givenname: Kent C.
  surname: Shih
  fullname: Shih, Kent C.
  organization: Sarah Cannon Research Institute/Tennessee Oncology
– sequence: 8
  givenname: Céleste
  surname: Lebbé
  fullname: Lebbé, Céleste
  organization: APHP Dermatology and CIC Departments, University Paris Diderot INSERM U976, Saint Louis Hospital
– sequence: 9
  givenname: Michele
  surname: Milella
  fullname: Milella, Michele
  organization: Regina Elena National Cancer Institute
– sequence: 10
  givenname: Isaac
  surname: Brownell
  fullname: Brownell, Isaac
  organization: National Cancer Institute
– sequence: 11
  givenname: Karl D.
  surname: Lewis
  fullname: Lewis, Karl D.
  organization: University of Colorado Denver, School of Medicine
– sequence: 12
  givenname: Jochen H.
  surname: Lorch
  fullname: Lorch, Jochen H.
  organization: Dana-Farber Cancer Institute
– sequence: 13
  givenname: Anja
  surname: von Heydebreck
  fullname: von Heydebreck, Anja
  organization: Merck KGaA
– sequence: 14
  givenname: Meliessa
  surname: Hennessy
  fullname: Hennessy, Meliessa
  organization: EMD Serono, Inc
– sequence: 15
  givenname: Paul
  surname: Nghiem
  fullname: Nghiem, Paul
  organization: University of Washington Medical Center at South Lake Union
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29347993$$D View this record in MEDLINE/PubMed
BookMark eNp9k0Fu1DAUhiNUREvpAdggS0iIBSm24zgxC6SqKlBUYEPZWo79MuPiiYOdtJ0jcAs2LLkER-EkOJ22dCpAkRLL-f7f9u_37mcbne8gyx4SvEtIzZ9Hhhktc0yqHBcE5-d3si2KS5ITRvnGjfFmthPjCcaY4KKo6_petklFwSohiq3sx3Fv1AAGQdtarfQS-RapU3DjQjXIdqhXg4VuiOjMDnPUBzi1foxuiYYAF8IFDCoOidLoHYTP4JAGl14qaNv5hUKqHSCgX1-_k5_flqDCtELrnfNn-di_QG_3Ph0cHb6_ElOMnyGF-rmKgCjSznZpXy4tZ5V7kN1tlYuwc_ndzo5fHXzcf5MffXh9uL93lGtesCEXpuHYqEZQoZloRc1b0dQVNSXGNWOcUsEIpywNjeCCGOBlRVpjoCEtJ6zYzg5XvsarE9kHu1BhKb2y8mLCh5lUIZ3YgawrTBuhNBRgGCgiygYEU0rxhhrMy-T1cuXVj80CjE5hBuXWTNf_dHYuZ_5UllWVdlklg6eXBsF_GSEOcmHjlLHqIF2FJKIWPF0tKRL6-BZ64sfQpagk5UWNRUkTdk3NVDqA7Vqf1tWTqdxLQFWwVE-J2v0LlR4DC6tTLbY2za8JntwQzEG5YR69Gwfru7gOPrqZyHUUV1WZgGoF6OBjDNBKbacK81NA1kmC5dQCctUCMrWAnFpAnicluaW8Mv-fhq40MbHdDMKf0P4t-g3z9Bhb
CitedBy_id crossref_primary_10_1016_j_ejca_2022_03_043
crossref_primary_10_3389_fonc_2020_00529
crossref_primary_10_1186_s40425_018_0479_7
crossref_primary_10_1111_exd_14520
crossref_primary_10_1016_j_critrevonc_2021_103464
crossref_primary_10_1016_j_ejca_2024_115121
crossref_primary_10_1111_ajd_13131
crossref_primary_10_1007_s00292_019_00705_7
crossref_primary_10_1007_s12325_019_01034_0
crossref_primary_10_1016_j_mayocpiqo_2019_09_005
crossref_primary_10_1080_14737140_2018_1528146
crossref_primary_10_1007_s40258_019_00492_5
crossref_primary_10_3390_cancers11091217
crossref_primary_10_1158_1078_0432_CCR_18_4159
crossref_primary_10_1111_ijd_16534
crossref_primary_10_1177_2324709619836695
crossref_primary_10_1007_s42399_022_01350_7
crossref_primary_10_2217_imt_2019_0011
crossref_primary_10_1007_s00432_019_02839_w
crossref_primary_10_1016_j_adengl_2021_03_016
crossref_primary_10_3390_cancers12071826
crossref_primary_10_1007_s00347_019_01034_z
crossref_primary_10_1111_bcp_14338
crossref_primary_10_1055_s_0044_1791935
crossref_primary_10_31487_j_COR_2019_05_04
crossref_primary_10_1007_s11523_018_0585_y
crossref_primary_10_1111_ijd_17297
crossref_primary_10_1111_bjd_20770
crossref_primary_10_1111_ced_14530
crossref_primary_10_1111_1346_8138_15621
crossref_primary_10_1007_s40257_019_00427_9
crossref_primary_10_2217_fon_2020_1313
crossref_primary_10_12998_wjcc_v9_i18_4829
crossref_primary_10_1186_s12885_018_4919_z
crossref_primary_10_1055_a_1587_2499
crossref_primary_10_1136_jitc_2022_004904
crossref_primary_10_1186_s40425_019_0798_3
crossref_primary_10_1007_s11912_021_01120_z
crossref_primary_10_1016_j_clon_2019_08_012
crossref_primary_10_1200_JCO_18_01896
crossref_primary_10_1200_PO_19_00098
crossref_primary_10_1093_jscr_rjz322
crossref_primary_10_3389_fonc_2023_1119369
crossref_primary_10_1634_theoncologist_2020_0184
crossref_primary_10_1200_JCO_19_02727
crossref_primary_10_3103_S0891416821020026
crossref_primary_10_1159_000502285
crossref_primary_10_1200_EDBK_278953
crossref_primary_10_2217_fon_2020_0453
crossref_primary_10_1016_j_jaad_2019_05_077
crossref_primary_10_2217_imt_2023_0105
crossref_primary_10_1186_s13256_024_04750_6
crossref_primary_10_1158_1078_0432_CCR_19_0972
crossref_primary_10_1093_intimm_dxz012
crossref_primary_10_1007_s00105_019_4360_5
crossref_primary_10_1016_j_clcc_2022_03_003
crossref_primary_10_3390_ijms19071873
crossref_primary_10_1136_jitc_2024_010006
crossref_primary_10_1186_s40425_018_0420_0
crossref_primary_10_36290_xon_2020_074
crossref_primary_10_1111_1346_8138_16232
crossref_primary_10_1186_s12874_020_00997_x
crossref_primary_10_1001_jamaoncol_2018_0077
crossref_primary_10_1007_s12022_019_09601_5
crossref_primary_10_1016_j_cellin_2024_100153
crossref_primary_10_1016_j_cell_2021_09_020
crossref_primary_10_3390_jcm11123364
crossref_primary_10_1002_jso_26048
crossref_primary_10_1016_j_det_2019_03_001
crossref_primary_10_1245_s10434_024_15478_4
crossref_primary_10_1007_s12020_023_03526_0
crossref_primary_10_1016_j_hoc_2021_05_008
crossref_primary_10_3390_antib9020017
crossref_primary_10_1016_j_soc_2019_02_008
crossref_primary_10_1002_cam4_4138
crossref_primary_10_3389_fimmu_2023_1253568
crossref_primary_10_3390_cancers13143415
crossref_primary_10_1177_2324709620963714
crossref_primary_10_1007_s00403_024_02853_0
crossref_primary_10_1007_s11654_019_0154_6
crossref_primary_10_1016_j_cpccr_2022_100155
crossref_primary_10_1245_s10434_020_08656_7
crossref_primary_10_1016_j_abd_2022_09_003
crossref_primary_10_1111_ddg_15214_g
crossref_primary_10_1016_j_ejca_2023_01_016
crossref_primary_10_1097_CCO_0000000000000508
crossref_primary_10_1016_j_soncn_2019_08_003
crossref_primary_10_1136_jitc_2020_000700
crossref_primary_10_3390_cancers15102696
crossref_primary_10_1016_j_cbpa_2018_05_006
crossref_primary_10_1111_1346_8138_14829
crossref_primary_10_1186_s12935_022_02816_3
crossref_primary_10_1007_s12328_023_01821_x
crossref_primary_10_1158_1078_0432_CCR_18_2355
crossref_primary_10_1200_JCO_24_02138
crossref_primary_10_3390_ijms22168679
crossref_primary_10_1002_ijc_31899
crossref_primary_10_1016_S1632_3475_20_43716_6
crossref_primary_10_1002_onco_13845
crossref_primary_10_3389_fmed_2019_00160
crossref_primary_10_1016_j_critrevonc_2022_103855
crossref_primary_10_1016_j_jval_2019_05_010
crossref_primary_10_3390_cancers12040888
crossref_primary_10_1080_14737140_2021_1835477
crossref_primary_10_1111_cts_13730
crossref_primary_10_1177_1060028018768809
crossref_primary_10_1200_JCO_20_00201
crossref_primary_10_1007_s11864_021_00866_9
crossref_primary_10_1016_j_piel_2019_03_005
crossref_primary_10_1016_j_mpdhp_2018_12_007
crossref_primary_10_1186_s12935_021_02407_8
crossref_primary_10_1007_s11864_018_0574_5
crossref_primary_10_1002_cncr_31293
crossref_primary_10_1016_j_canrad_2021_07_006
crossref_primary_10_1016_j_jid_2021_02_006
crossref_primary_10_1007_s15012_018_2610_3
crossref_primary_10_3389_fimmu_2020_592721
crossref_primary_10_29413_ABS_2021_6_4_13
crossref_primary_10_1080_21645515_2020_1854604
crossref_primary_10_1097_CCO_0000000000000608
crossref_primary_10_1080_14712598_2021_1981284
crossref_primary_10_1177_17588359241255628
crossref_primary_10_1002_cam4_5890
crossref_primary_10_3389_fmicb_2021_739695
crossref_primary_10_1186_s12967_020_02627_y
crossref_primary_10_59449_joco_2023_09_11
crossref_primary_10_3390_cancers15205084
crossref_primary_10_1002_ski2_9
crossref_primary_10_18794_aams_188363
crossref_primary_10_3390_cancers12040919
crossref_primary_10_3389_fimmu_2023_1122352
crossref_primary_10_1007_s10585_021_10132_9
crossref_primary_10_1146_annurev_pathol_042020_042741
crossref_primary_10_1007_s11154_021_09647_z
crossref_primary_10_17116_molgen20213902114
crossref_primary_10_1007_s00262_019_02341_9
crossref_primary_10_3390_jpm13050841
crossref_primary_10_1016_j_tranon_2020_100816
crossref_primary_10_3389_fonc_2019_00223
crossref_primary_10_3390_cancers12030554
crossref_primary_10_1016_j_ad_2024_10_017
crossref_primary_10_3390_cancers13020265
crossref_primary_10_2147_CCID_S361844
crossref_primary_10_1007_s11904_020_00525_y
crossref_primary_10_1007_s13671_018_0246_5
crossref_primary_10_3390_ijms21155394
crossref_primary_10_1634_theoncologist_2018_0718
crossref_primary_10_1136_jitc_2022_004742
crossref_primary_10_3389_fimmu_2021_720748
crossref_primary_10_1007_s12105_020_01164_w
crossref_primary_10_1371_journal_pone_0252099
crossref_primary_10_3390_cancers14010109
crossref_primary_10_1016_j_cell_2020_02_019
crossref_primary_10_3389_fonc_2021_739006
crossref_primary_10_1039_D1CP01281A
crossref_primary_10_1111_1754_9485_13243
crossref_primary_10_1002_mc_23483
crossref_primary_10_1016_j_jpra_2022_05_005
crossref_primary_10_1177_1758835920937612
crossref_primary_10_1055_a_1219_3728
crossref_primary_10_1136_jitc_2021_004434
crossref_primary_10_1002_onco_13887
crossref_primary_10_1016_j_semradonc_2018_11_012
crossref_primary_10_1080_17512433_2018_1445966
crossref_primary_10_1007_s13555_020_00424_5
crossref_primary_10_1093_epirev_mxz003
crossref_primary_10_3390_cells8040320
crossref_primary_10_1007_s00761_021_00939_2
crossref_primary_10_2147_POR_S398151
crossref_primary_10_1111_ddg_14930_g
crossref_primary_10_1080_21645515_2018_1551671
crossref_primary_10_3389_fimmu_2024_1346178
crossref_primary_10_1097_DAD_0000000000001287
crossref_primary_10_2217_fon_2020_1250
crossref_primary_10_21518_2079_701X_2020_9_94_100
crossref_primary_10_1007_s00280_019_03925_z
crossref_primary_10_1016_j_tvr_2021_200232
crossref_primary_10_3390_dermato3010003
crossref_primary_10_4103_ijmpo_ijmpo_165_18
crossref_primary_10_1111_jdv_15352
crossref_primary_10_3389_fimmu_2020_568931
crossref_primary_10_1136_jitc_2020_001098
crossref_primary_10_1111_1754_9485_13039
crossref_primary_10_18632_oncotarget_27823
crossref_primary_10_1002_psp4_12406
crossref_primary_10_1016_j_hoc_2024_05_013
crossref_primary_10_3390_cancers12040832
crossref_primary_10_1016_j_tcb_2019_01_003
crossref_primary_10_1016_S1639_870X_19_43312_6
crossref_primary_10_1007_s00262_023_03387_6
crossref_primary_10_1038_s41379_019_0261_5
crossref_primary_10_1111_ddg_15214
crossref_primary_10_1186_s40425_019_0661_6
crossref_primary_10_1007_s11523_018_0571_4
crossref_primary_10_3389_fphar_2021_583126
crossref_primary_10_1007_s00105_021_04799_0
crossref_primary_10_1007_s40271_020_00428_5
crossref_primary_10_1136_jitc_2019_000313
crossref_primary_10_1055_a_1337_0882
crossref_primary_10_1111_ddg_13841_g
crossref_primary_10_1136_jitc_2020_000674
crossref_primary_10_3390_v13050822
crossref_primary_10_1016_j_bbcan_2023_188880
crossref_primary_10_1159_000490636
crossref_primary_10_1111_ddg_13841
crossref_primary_10_2147_CEOR_S290768
crossref_primary_10_1111_1346_8138_15543
crossref_primary_10_1186_s13073_021_00946_3
crossref_primary_10_1111_ddg_14930
crossref_primary_10_1016_j_bulcan_2018_11_009
crossref_primary_10_3390_immuno4030013
crossref_primary_10_1016_j_jid_2020_08_023
crossref_primary_10_1016_j_smim_2019_101295
crossref_primary_10_1136_jitc_2020_001076
crossref_primary_10_1111_jdv_15335
crossref_primary_10_1055_a_1925_7703
crossref_primary_10_1111_jdv_20481
crossref_primary_10_1016_j_ctro_2018_12_004
crossref_primary_10_1055_a_2214_5209
crossref_primary_10_1007_s00105_019_4465_x
crossref_primary_10_1007_s00761_018_0483_z
crossref_primary_10_1097_IIO_0000000000000306
crossref_primary_10_5935_2526_8732_20230404
crossref_primary_10_1177_11795549241298541
crossref_primary_10_3390_vaccines8030419
crossref_primary_10_1016_j_ad_2019_07_020
crossref_primary_10_2217_imt_2021_0089
crossref_primary_10_1016_j_semcancer_2020_06_016
crossref_primary_10_1038_s41379_019_0394_6
crossref_primary_10_1177_2050313X211023685
crossref_primary_10_18027_2224_5057_2019_9_1_53_58
crossref_primary_10_3390_jcm8101667
crossref_primary_10_1055_s_0041_1740949
crossref_primary_10_1002_mc_23042
crossref_primary_10_1002_cnr2_1160
crossref_primary_10_1016_j_ejca_2024_114261
crossref_primary_10_3389_fendo_2022_1038181
crossref_primary_10_7759_cureus_18276
crossref_primary_10_1016_j_ad_2024_01_023
crossref_primary_10_1016_j_jaad_2020_03_131
crossref_primary_10_1016_j_jid_2019_06_125
crossref_primary_10_1007_s12094_020_02338_2
crossref_primary_10_1016_j_hoc_2018_08_002
crossref_primary_10_3390_ijms22126305
Cites_doi 10.1016/S1470-2045(16)30364-3
10.1002/cam4.815
10.1016/j.ejca.2016.10.022
10.2217/fon-2017-0187
10.1016/j.ejca.2015.06.131
10.1200/JCO.2005.02.329
10.1016/j.ejca.2008.10.026
10.1158/1538-7445.AM2017-CT074
10.1056/NEJMoa1603702
10.1097/CCO.0000000000000363
10.2217/fon-2017-0072
10.1080/2162402X.2017.1338237
ContentType Journal Article
Copyright The Author(s). 2018
COPYRIGHT 2018 BioMed Central Ltd.
2018 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/ ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/ ) applies to the data made available in this article, unless otherwise stated. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s). 2018
– notice: COPYRIGHT 2018 BioMed Central Ltd.
– notice: 2018 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/ ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/ ) applies to the data made available in this article, unless otherwise stated. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s40425-017-0310-x
DatabaseName Springer Nature OA Free Journals
CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ - The Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList PubMed
Publicly Available Content Database
MEDLINE - Academic


Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2051-1426
EndPage 7
ExternalDocumentID oai_doaj_org_article_8702b9ace3ed4ea195be94aaa6b2d065
PMC5774167
A523734310
29347993
10_1186_s40425_017_0310_x
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Merck KGaA, Darmstadt, Germany
– fundername: Pfizer Inc.
– fundername: ;
GroupedDBID 4.4
53G
5VS
7X7
88E
8FI
8FJ
9YT
ABUWG
ACGFS
ADBBV
ADRAZ
ADUKV
AFKRA
AHBYD
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AOIJS
ASPBG
AVWKF
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
DIK
EBS
EJD
FYUFA
GROUPED_DOAJ
H13
HMCUK
HYE
IAO
IHR
IHW
INH
INR
ITC
KQ8
M1P
M48
M~E
OK1
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
RBZ
RMJ
ROL
RPM
RSV
SOJ
UKHRP
AAYXX
ALIPV
CITATION
-A0
3V.
ABDBF
ACRMQ
ADINQ
C24
NPM
PMFND
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c634t-9db60dab929c49f986f9b872d500844622941624446d9691de6571fddeb1f6143
IEDL.DBID M48
ISSN 2051-1426
IngestDate Wed Aug 27 01:25:46 EDT 2025
Thu Aug 21 13:43:08 EDT 2025
Fri Sep 05 05:00:30 EDT 2025
Fri Jul 25 20:14:43 EDT 2025
Tue Jun 17 21:47:50 EDT 2025
Tue Jun 10 20:41:05 EDT 2025
Thu May 22 21:08:22 EDT 2025
Thu Jan 02 23:03:28 EST 2025
Tue Jul 01 01:55:44 EDT 2025
Thu Apr 24 23:09:53 EDT 2025
Sat Sep 06 07:27:21 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Avelumab
Javelin
Pd-L1
Merkel cell carcinoma
Language English
License Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c634t-9db60dab929c49f986f9b872d500844622941624446d9691de6571fddeb1f6143
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s40425-017-0310-x
PMID 29347993
PQID 2638095231
PQPubID 2040222
ParticipantIDs doaj_primary_oai_doaj_org_article_8702b9ace3ed4ea195be94aaa6b2d065
pubmedcentral_primary_oai_pubmedcentral_nih_gov_5774167
proquest_miscellaneous_1989603313
proquest_journals_2638095231
gale_infotracmisc_A523734310
gale_infotracacademiconefile_A523734310
gale_healthsolutions_A523734310
pubmed_primary_29347993
crossref_citationtrail_10_1186_s40425_017_0310_x
crossref_primary_10_1186_s40425_017_0310_x
springer_journals_10_1186_s40425_017_0310_x
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-01-19
PublicationDateYYYYMMDD 2018-01-19
PublicationDate_xml – month: 01
  year: 2018
  text: 2018-01-19
  day: 19
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Journal for immunotherapy of cancer
PublicationTitleAbbrev j. immunotherapy cancer
PublicationTitleAlternate J Immunother Cancer
PublicationYear 2018
Publisher BioMed Central
BioMed Central Ltd
BMJ Publishing Group LTD
BMJ Publishing Group
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
– name: BMJ Publishing Group LTD
– name: BMJ Publishing Group
References PT Nghiem (310_CR7) 2016; 374
JG Iyer (310_CR15) 2016; 5
PJ Allen (310_CR4) 2005; 23
D Schadendorf (310_CR3) 2017; 71
P Nghiem (310_CR6) 2017; 13
CL Cowey (310_CR13) 2017; 13
310_CR12
Bavencio (310_CR10) 2017
310_CR14
C Lebbe (310_CR1) 2015; 51
310_CR16
EA Eisenhauer (310_CR11) 2009; 45
HL Kaufman (310_CR8) 2016; 17
310_CR9
NCCN (310_CR5) 2018
310_CR2
References_xml – volume: 17
  start-page: 1374
  issue: 10
  year: 2016
  ident: 310_CR8
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(16)30364-3
– volume: 5
  start-page: 2294
  issue: 9
  year: 2016
  ident: 310_CR15
  publication-title: Cancer Med
  doi: 10.1002/cam4.815
– volume: 71
  start-page: 53
  year: 2017
  ident: 310_CR3
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2016.10.022
– volume: 13
  start-page: 1699
  issue: 19
  year: 2017
  ident: 310_CR13
  publication-title: Future Oncol
  doi: 10.2217/fon-2017-0187
– volume: 51
  start-page: 2396
  issue: 16
  year: 2015
  ident: 310_CR1
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2015.06.131
– volume: 23
  start-page: 2300
  issue: 10
  year: 2005
  ident: 310_CR4
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.02.329
– volume-title: Clinical practice guidelines in oncology: Merkel cell carcinoma
  year: 2018
  ident: 310_CR5
– volume: 45
  start-page: 228
  issue: 2
  year: 2009
  ident: 310_CR11
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2008.10.026
– volume-title: (avelumab) injection [package insert]
  year: 2017
  ident: 310_CR10
– ident: 310_CR14
  doi: 10.1158/1538-7445.AM2017-CT074
– ident: 310_CR12
  doi: 10.1158/1538-7445.AM2017-CT074
– volume: 374
  start-page: 2542
  issue: 26
  year: 2016
  ident: 310_CR7
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1603702
– ident: 310_CR9
  doi: 10.1158/1538-7445.AM2017-CT074
– ident: 310_CR2
  doi: 10.1097/CCO.0000000000000363
– volume: 13
  start-page: 1263
  issue: 14
  year: 2017
  ident: 310_CR6
  publication-title: Future Oncol
  doi: 10.2217/fon-2017-0072
– ident: 310_CR16
  doi: 10.1080/2162402X.2017.1338237
SSID ssj0001033888
Score 2.5396335
Snippet Background Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with poor survival outcomes in patients with distant metastatic disease...
Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with poor survival outcomes in patients with distant metastatic disease (mMCC). In an...
BackgroundMerkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with poor survival outcomes in patients with distant metastatic disease...
Abstract Background Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with poor survival outcomes in patients with distant metastatic...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 7
SubjectTerms Analysis
Avelumab
Cancer
Care and treatment
Chemotherapy
Clinical trials
Clinical/Translational Cancer Immunotherapy
Development and progression
Estimates
FDA approval
Hematology
Immunology
Immunotherapy
Javelin
Ligands
Medical prognosis
Medicine
Medicine & Public Health
Merkel cell carcinoma
Metastasis
Monoclonal antibodies
Oncology
Patients
Pd-L1
Response rates
Short Report
Skin cancer
Targeted cancer therapy
Tumors
SummonAdditionalLinks – databaseName: DOAJ - The Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbhMxELZQD4gL4p-FAkZCQgKs7o_Xu-YWUKtSkZ4I6s3y36oR6WbVJG3zCLwFF468BI_CkzDj3YRsEXDhGttaZ2Y8_sYef0PIM88NEmVlzKfGM85tzCCMsEz4hKdO6LjK8XHy8FDsj_jBUX60UeoLc8JaeuBWcDtgT6mR2vrMO-51InPjJddaC5M62D_R-8Yy3gimwulKDKFXWXbXmEkpdmYczZOhU0Y2THbR24gCX__vXnljW7qcMnnp3jRsR3s3yPUOR9JBO_-b5Iqvb5Grw-6m_Db5NmowlnfUI0eEtks6rag-8-CLtKHjmnaEqjOKJ7G0wWzf6WI2WdKQeg4DT_xc43OjsaVDf_rJTyge8lOLxYfq6Ymmobw4_fH5a_L9yxIWDH6hArOanrNF85oeDD7uvn93uBoM6-QV1bQ5hm2TpnT1IpOGsiF3yGhv98PbfdaVZmBWZHzOpDMidtoAuLJcVrIUlTRlkbocCfq5SFMJSA-gAxdOCpk4L_IiqcCXmqQCRJDdJVv1tPb3CS0qa7Swhovc80xUZVZxWcal0Q6gpjMRiVd6UrbjLcfyGRMV4pdSqFa1ClSrULXqIiIv1kOalrTjb53foPLXHZFvO_wAVqg6K1T_ssKIPEHTUe3j1bXXUAOI84sMQFockeehB_oNmD4ovn3-AEJABq5ez-1eT1jvtt-8Mk_V-ZuZSsGNAlgGsB6Rp-tmHIk5dLUHA1KYHSdgXSRZRO611rz-0wD6eAFQNSJFz857Uum31OPjwEaeFwjqi4i8XK2IX9P6o9Af_A-hPyTXAL5iLiZL5DbZmp8u_COAiHPzOHiDnznPZEw
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3bbtQwELXKVkK8IO4EChgJCQmImovjxEgIbdFWpWJXCLGob5ZvoSvaJOwFup_Ah_DGV_ElzGSTXVJEX2NbSTwXH9szZwh54phGoqzYd5F2PmMm8GEbYXzuQhZZroI8weTk4YgfjNnhUXK0RUZtLgyGVbY-sXbUtjR4Rr4bgaIAHAA48rr66mPVKLxdbUtoqKa0gn1VU4xdItsRVlXuke29wej9h82pSwBbsixrrjfDjO_OGKqtj84aWTL9s84CVfP4_-ut_1quzodSnrtPrZep_WvkaoMvaX-lENfJlitukMvD5gb9Jvk1rnCPb6lD7ghllrTMqfrmwEcpTScFbYhWZxRPaGmFUcDlYnaypHVIOgw8dXOFaUgTQ4du-sWdUDz8pwaLEhXlqaJ12XH6-8fPkC7BjvAFOWhb-d1fVC_pYf_T4N3bUTsWzOcFVbQ6htWURrRN1KR1NZFbZLw_-PjmwG8qNviGx2zuC6t5YJUGzGWYyEXGc6GzNLIJ8vYzHkUCACAgCsat4CK0jidpmIOL1WEOQCG-TXpFWbi7hKa50YobzXjiWMzzLM6ZyIJMKwsI1GqPBK2YpGnozLGqxomstzUZlyvJSpCsRMnKM488Ww-pVlweF3XeQ9mvOyINd_2gnH6WjVVLcHaRFsq42FnmVCgS7QRTSnEdWQB3HnmEmiNXOa1rZyL7oMdpDNgt8MjTuge6E_h8kPsqKwImAYm5Oj13Oj3BDZhuc6udsnFDM7kxGo88XjfjSAytKxzoj8SgOQ5mEcYeubNS5vVPAxZkKSBYj6QdNe_MSrelmBzXJOVJilg_9cjz1iA2n_XfSb938U_cJ1cAr2LwpR-KHdKbTxfuAWDCuX7YGPofpvlf8A
  priority: 102
  providerName: ProQuest
– databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3bbtNAEF2hIiFeEHcMBQYJCQlY4ct67eUtRK1KRfpEUN9We7MaNXWiJgX6CfwFLzzyE3wKX8KM7aR1uUi8xrOys3PZM7szZxl7GoQloqyMh9QGLoSLOaYRjsuQiNRLE1c5NSeP9uTOWOzu5_sdWTT1wpw_v09K-WohyKo4xVIiseQIFy_nGHepem8oh2fbKTHmWmXZnVv-cWRv5WkI-n8Pw-fWoYs1khcOSpv1Z_s6u9YBRxi0mr7BLoX6Jrsy6o7Gb7Hv4zkl7x4CkUIYdwqzCszHgMHHWJjU0DGoLoC2XmFO5b2Y9U9Poak1x4FHYWmov2jiYBSOD8MUaFcfHN02VM-ODDT3icPPL9-SH19P0UPoDRXa0ewTP5m_ht3Bh613b_dWg9ExXoKB-QGuk5DCqgUTmntCbrPx9tb74Q7v7mLgTmZiyZW3MvbGIppyQlWqlJWyZZH6nBj5hUxThdAOsYKQXkmV-CDzIqkweNqkQgiQ3WEb9awO9xgUlbNGOitkHkQmqzKrhCrj0hqP2NLbiMUrPWnXEZXTfRlT3SQspdStajWqVpNq9eeIPV8PmbcsHf8SfkPKXwsSwXbzA9qd7vxVYxhLrTIuZMGLYBKV26CEMUba1CNsi9hjMh3ddquuw4QeYGJfZIjK4og9ayQoUODno-LbfgecBKLc6klu9iTRwV3_8co8dRdgFjrFuInoGNF5xJ6sH9NIKpqrAxqQpnI4iX6RZBG721rz-k8jyhMFYtOIFT07781K_0k9OWjox_OCUHwRsRcrjzj7rL9O-v3_kn7AriIwpSpLnqhNtrE8PgkPEfwt7aPG7X8BVLZThA
  priority: 102
  providerName: Springer Nature
Title Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
URI https://link.springer.com/article/10.1186/s40425-017-0310-x
https://www.ncbi.nlm.nih.gov/pubmed/29347993
https://www.proquest.com/docview/2638095231
https://www.proquest.com/docview/1989603313
https://pubmed.ncbi.nlm.nih.gov/PMC5774167
https://doaj.org/article/8702b9ace3ed4ea195be94aaa6b2d065
Volume 6
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dbtMwFLbGJiFuEP8ERjESEhKQkR_HiZEQ6qpOY6IVQhTtzrITh1V0SekPrI_AW3DDJS_Bo_AknOMkhYzBBZetbSXx-fFn-5zvEHLfMI1EWaFrAm1cxlLPhW1E6nLjsyDjyssjTE4eDPn-iB0cRocbpClvVU_g_MytHdaTGs0mOycfVs_B4J9Zg0_4kzlDzXPR3yLRpQuQcgsWpgCVfFCjfXvk4sF-LEnqu80zRyI3sMDkShG2FirL5_-n1_5t2TodUnnqXtUuV3uXyMUaZ9JupRiXyYYprpDzg_om_Sr5NpriXj-jBjkkVLqiZU7VRwO-Smk6LmhNuDqneFJLpxgNXC7nkxW1oekw8NgsFKYjjVM6MLP3ZkLxEoCmWJyoKI8VteXH6Y_PX_3vX1ZgUPiEHNSu_OQup0_pQfdt_-WLYTMY7OgxVXR6BMsqDWiTsUltWZFrZLTXf9Pbd-vSDW7KQ7ZwRaa5lykN4CtlIhcJz4VO4iCLkMCf8SAQgAQBWjCeCS78zPAo9nPwtdrPATGE18lmURbmJqFxnmrFU814ZFjI8yTMmUi8RKsMoGimHeI1cpJpzWuO5TUm0u5vEi4rKUuQskQpyxOHPFwPmVakHv_qvIvCX3dEPm77Rzl7J2vzluD1Ai1UakKTMaN8EWkjmFKK6yADlOeQu6g6skpuXXsV2Y2CMA4BxHkOeWB7oKbD64Pgq_QImARk6Gr13G71BH-Qtpsb9ZSNOckA3CyAaQDzDrm3bsaRGGNXGFAgidFzHEzEDx1yo9Lm9Uc3RuGQuKXnrVlptxTjI8tWHsUI-mOHPGos4tdr_XXSb_33c26TC4BpMUDT9cU22VzMluYO4MaF7pBz8WHcIVu7_eGr1_Crx3sdewbTsX7iJ8Bib48
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3ZbtNAFB2VVgJeEDuGQgcJhARY9TIe20gVaiFVt0QINVXfhtlMK1LbNAltPoEP4Y1v4GP4Eu517BQX0be-ZmYce-527sxdCHlmmcJCWaFrA2VdxrTnghuhXW59FhguvSzC5ORuj2_02dZ-tD9HfjW5MBhW2ejESlGbQuMZ-XIAjAJwAODI2_Kri12j8Ha1aaEh69YKZqUqMVYndmzbyQm4cMOVzfdA7-dBsN7Zfbfh1l0GXM1DNnJTo7hnpAKcoFmapQnPUpXEgYmw1jzjQZACaAEryLhJeeoby6PYz0AtKD8D4xbCc6-QBYAdIUjVwlqn9-Hj2SmPBy5gktTXqX7Cl4cMxcRF44BVOd3TlkGs-gb8ax3-Mo_nQzfP3d9WZnH9JrlR41m6OmXAW2TO5rfJ1W59Y3-H_OyXeKZgqMVaFVJPaJFR-c2CTpSKHua0Luw6pHgiTEuMOi7Gw8GEViHwsPDIjiSmPR1q2rXHX-yA4mUD1dgEKS-OJK3anNPf33_4dAIEwT_IgLuLE3dcvqFbq3udnc1esxbE9TWVtDwA600D2iSG0qp7yV3SvxTa3SPzeZHbB4TGmVaSa8V4ZFnIsyTMWJp4iZIGEK9RDvEaMgldl0_HLh4DUblRCRdTygqgrEDKilOHvJwtKae1Qy6avIa0n03Est_VD8XxZ1FrEQHKNVCp1Da0hlnpp5GyKZNSchUYAJMOWULOEdMc2pnyEqsgN3EIWNFzyItqBqoveH2g-zQLAzYBC4G1Zi62ZoLa0e3hhjtFrfaG4kxIHfJ0NowrMZQvt8A_AoP0OIiFHzrk_pSZZx8N2JPFgJgdErfYvLUr7ZH88KAqih7F6FvEDnnVCMTZa_130x9e_BFL5NrGbndHAJduPyLXAStj4Kfrp4tkfnQ8to8Bj47Uk1roKfl02XrmD8oPmws
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbtQwELVKkSpeEHcChRoJhAREm4vjJEgILbSrXtiKBxbtm7Edh67YJmEvtPsJfAhvfAGfw5cwk8suKaJvfV3b2cQzc2bGngshjw1TWCjLt42njM2YdmxwI7TNjcu8hEsnDTA5uX_IdwdsfxgM18ivJhcGwyobTCyBOsk1npF3PGAUMAfAHOmkdVjE--3e6-KrjR2k8Ka1aadRsciBWZyA-zZ9tbcNtH7ieb2dD2937brDgK25z2Z2nCjuJFKBjaBZnMYRT2MVhV4SYJ15xj0vBoMFNCDjScxjNzE8CN0UIEG5KSg2H557iVwOfVDrIEvhMFyd7zjg_EVRfZHqRrwzZSggNqoFrMdpn7ZUYdkx4F-98JdiPBu0eebmtlSIvWvkam3J0m7FetfJmslukI1-fVd_k_wcFHiakFCDVSqkXtA8pfKbATSUio4yWpd0nVI8C6YFxhvn8-l4Qcvgd1h4bGYSE55GmvbN5IsZU7xmoBrbH2X5saRlg3P6-_sPly6AHPgHKfB1fmLPi5d0v_tx593eYbMWBPUFlbQ4Ar1NPdqkhNKyb8ktMrgQyt0m61membuEhqlWkmvFeGCYz9PIT1kcOZGSCdi6ibKI05BJ6LpwOvbvGIvSgYq4qCgrgLICKStOLfJsuaSoqoacN_kN0n45EQt-lz_kk8-ixg8BsOqpWGrjm4QZ6caBMjGTUnLlJWBGWmQLOUdU2bNL2BJdkBhkT9exyNNyBgIXvD7Qvcq_gE3AEmCtmZutmQA4uj3ccKeoAW8qVuJpkUfLYVyJQXyZAf4RGJ7HQSxc3yJ3KmZefjRYnSwEW9kiYYvNW7vSHslGR2U59CBEryK0yPNGIFav9d9Nv3f-R2yRDUAXAUx6cJ9cASMZIz5tN94k67PJ3DwAQ3SmHpYST8mni4aYP4damKc
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Updated+efficacy+of+avelumab+in+patients+with+previously+treated+metastatic+Merkel+cell+carcinoma+after+%E2%89%A51%C2%A0year+of+follow-up%3A+JAVELIN+Merkel+200%2C+a+phase+2+clinical+trial&rft.jtitle=Journal+for+immunotherapy+of+cancer&rft.au=Kaufman%2C+Howard+L.&rft.au=Russell%2C+Jeffery+S.&rft.au=Hamid%2C+Omid&rft.au=Bhatia%2C+Shailender&rft.date=2018-01-19&rft.pub=BioMed+Central&rft.eissn=2051-1426&rft.volume=6&rft_id=info:doi/10.1186%2Fs40425-017-0310-x&rft_id=info%3Apmid%2F29347993&rft.externalDocID=PMC5774167
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2051-1426&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2051-1426&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2051-1426&client=summon